Domo signs strategic collaboration agreement with AWS for AI solutions
Arturo Molina, the Chief Medical (TASE:PMCN) Officer of Protagonist Therapeutics, Inc. (NASDAQ:PTGX), a $2.2 billion market cap biotech company, recently reported the sale of 3,640 shares of common stock on January 16, 2025. The transactions were executed to cover tax withholding obligations incurred upon the settlement of restricted stock units. The stock, currently trading at $36.82, has shown significant volatility according to InvestingPro data. Following these transactions, Dr. Molina holds 83,892 shares in the company. The shares were sold at a price of $0.00, reflecting their purpose for tax obligations rather than market transactions. InvestingPro analysis indicates the company maintains excellent financial health with a P/E ratio of 13.15 and strong cash position. Discover more insights about PTGX and 1,400+ other stocks with InvestingPro's comprehensive research reports.
In other recent news, Protagonist Therapeutics reported a shift in executive roles, with Suneel Gupta transitioning to Executive Vice President, Clinical Development. The company also received positive analyst ratings and price targets from firms such as Clear Street, BTIG, BMO Capital, and Truist Securities. These ratings highlight the potential of drug candidates rusfertide and icotrokinra, as well as Protagonist's PN-881. Additionally, Protagonist Therapeutics has seen significant progress in its collaboration with Takeda on the Rusfertide program for polycythemia vera treatment and has announced its entry into the obesity treatment market. Changes in the company's board were also noted, with Sarah A. O'Dowd filling a vacancy on the Audit Committee and the appointment of Newman Yeilding, M.D., as Chief Scientific Advisor. These are recent developments for Protagonist Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.